Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 301 - 350 out of 103,389

Document Document Title
WO/2014/155387A1
The present invention relates to extended release dosage forms of weakly basic drugs. Particularly the present invention is related to extended release dosage forms of quetiapine or pharmaceutically acceptable salts thereof.  
WO/2014/157047A1
The present invention relates to a therapeutic agent for neurodegenerative diseases, which contains a compound represented by formula (I) or a salt thereof. (In the formula, Ar1 represents an aromatic group; X represents a single bond or...  
WO/2014/159662A1
The present invention relates to the fields of medicine, cell biology, molecular biology and genetics. In particular, the present invention provides methods to isolate and purify microvesicles from cell culture supernatants and biologica...  
WO/2014/158916A1
The invention provides a chemical entity of Formula (I), wherein R1, R2, R3, Y, and n have any of the values described herein and compositions comprising such chemical entities; methods of making them; and and their use in a wide range o...  
WO/2014/160811A1
The invention features XIB4035 for the treatment of large fiber neuropathy, and combinations of XIB4035and GDNF for the treatment of both large and small fiber neuropathies.  
WO/2014/157803A1
The present invention relates to a composition for a GABAA-benzodiazepine receptor activation, which includes, as an active ingredient, an extract of at least one shellfish selected from among Mytilus edulis, Tegillarca granosa and Merce...  
WO/2014/160197A1
Provided herein are compounds of the formula (I) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing ...  
WO/2014/154131A1
Provided are a caffeoyl substituted pentacyclic triterpene derivative as represented by formula (I) and pharmaceutical composition containing the same. Also provided are uses of the derivative in the preparation of drugs or health-care p...  
WO/2014/158165A1
A composition for inducing erythropoietin (EPO)-mediated haemoglobin (Hb) expression in a nonhaematopoietic cell of a subject is provided. The composition includes a compound represented by formula (I), wherein R is a glycosyl group; and...  
WO/2014/160077A1
This disclosure relates to the use of a composition comprising opioid/Toll-like receptor 4 (TLR4) antagonists (opioid antagonists that treats pain by blocking Toll-like receptor 4 (TLR4)) and dextro enantiomers thereof for the treatment ...  
WO/2014/158998A1
The invention provides a chemical entity of Formula (I), and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection an...  
WO/2014/157158A1
Provided is a compound with strong human S1P2 antagonistic activity in order to develop drug products that are useful for treating S1P2 mediated disorders such as disorders that cause constriction of blood vessels, fibrosing disease, res...  
WO/2014/160102A1
The present invention generally relates to compositions and methods for treatment of subjects in need of muscle growth, muscle repair, improved muscular and neuromuscular control, and treatments for neuromuscular and neurological disorde...  
WO/2014/160480A8
(3alpha, 3beta)-disubstituted 17beta steroidal compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, are provided for the prevention and treatment of a variety of CNS- related conditions.  
WO/2014/154158A1
A traditional Chinese medicine composition for treating depression, and a preparation method therefor. Raw pharmaceutical ingredients of the traditional Chinese medicine composition comprise epimedium, prepared fleece-flower roots, and a...  
WO/2014/158059A1
The essence of the invention consists in a method for treating addiction, comprising pharmacotherapy with the use of medicinal homeopathic remedies, and also reflexotherapy with the stimulation of biologically active points (BAP) in comb...  
WO/2014/158547A1
This invention relates to methods and compositions for use improving cell viability, particularly neural cell viability, and more particularly to methods and compositions for use improving cell viability by reducing reactive oxygen metab...  
WO/2014/155332A1
This invention relates to the use of 25-hydroxyvitamin D3 (25-OH D3) to increase or maintain or alternatively, to lessen the decrease of the cognitive element known as executive functioning in healthy individuals. Optionally, 25-OH D3 ma...  
WO/2014/155056A1
A galactooligosaccharide composition comprising a mixture of disaccharides, trisaccharides, a tetrasaccharide and a pentasaccharide for use in preventing or treating cognitive dysfunction and/or emotional disturbances in neuropsychiatric...  
WO/2014/157635A1
The purpose of the present invention is to provide a drug that demonstrates a pharmaceutical effect by having high mobility to the mid-brain and converting to bumetanide in the mid-brain, which is the primary site of epilepsy. The presen...  
WO/2014/157569A1
Provided is a compound having an excellent JAK-inhibiting effect, the compound being is useful as an agent for the prevention or treatment of autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syn...  
WO/2014/154896A1
The present invention relates to novel compounds of Formula I, and their use in therapeutic treatments.  
WO/2014/160181A1
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing...  
WO/2014/157380A1
Provided is a means whereby wounds or organ fibrosis can be easily treated within a short period of time. A therapeutic agent for wounds or fibrosis, said therapeutic agent comprising a substance capable of specifically inhibiting the ex...  
WO/2014/159501A3
Disclosed are processes for preparing tetrahydroisoquinolines, intermediates useful in the preparation of tetrahydroisoquinolines, processes for preparing such intermediates, and compositions comprising the tetrahydroisoquinolines and ot...  
WO/2014/160423A1
The present invention includes compositions and methods for treating certain conditions, the composition comprising a choline compound; a cholinesterase inhibitor; and Acetyl-L-Carnitine, wherein the composition is used to treat at least...  
WO/2014/155184A1
A method for treating Parkinson's disease in a mammal in need thereof is disclosed. The method comprises administering to the mammal an effective amount of a compound of any one of Structural Formulas (I-III), or a pharmaceutically accep...  
WO/2014/157107A1
[Problem] To provide a polypeptide which has highly homogeneous sialylated sugar chains attached thereto and has an interferon β activity. [Solution] A sugar chain-containing polypeptide that is selected from the group consisting of (1)...  
WO/2014/155186A1
The invention relates to a food supplement comprising isomaltulose, whey protein concentrate, linseed, whey mineral complex, short-chain fructooligosaccharides, lactoferrin, and vitamin B6. This food supplement was developed to be used a...  
WO/2014/160502A1
This disclosure relates to uridine nucleoside derivatives, compositions comprising therapeutically effective amounts of those nucleoside derivatives and methods of using those nucleoside derivatives or compositions in treating disorders ...  
WO/2014/154897A1
The present invention relates to novel compounds of Formula (I) and their use in therapeutic treatments.  
WO/2014/159591A1
The present invention is directed to compounds of Formula I: wherein ring A is phenyl, naphihalenyl, pyridyl, quinolinyl, isoquinolinyl, imidazopyridyl, furanyi, tlisazolyl, isoxazolvl, pyrazolyl, imidazothiazolyi, benzimidazolyl, or ind...  
WO/2014/155351A1
A composition comprises as active ingredient an extract of a plant or plants from the Mesembryanthemaceae family, such as Mesembryanthemum tortuosum, having an alkaloid profile comprising at least 70% (w/w) stabilized mesembrine. The ext...  
WO/2014/160480A1
3beta, 17beta disubstituted steroidal compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, are provided for the prevention and treatment of a variety of CNS-related conditions.  
WO/2014/160138A3
The present invention generally relates to compositions and methods for topical or transdermal delivery, including treatment and prevention of learning and memory disorders, and enhancement of learning or memory. In some cases, the compo...  
WO/2014/147178A1
The present invention relates to Histone deacetylases 6 (HDAC6) inhibitors and compositions containing the same. Methods of treating diseases and conditions wherein inhibition of HDAC6 provides a benefit, like a cell proliferative diseas...  
WO/2014/151752A1
Provided herein are methods of treating a peripheral nerve injury in a subject. The methods include administering to the subject at or near the site of the peripheral nerve injury an effective amount of a composition comprising an agent ...  
WO/2014/152917A3
Provided herein are compounds capable of activating GPR139. Also provided are methods of increasing and decreasing the activity of GPR139. Methods of using the identified compounds to modulate GPR139 activity or conditions that may be af...  
WO/2014/148574A1
The purpose of the present invention is to find a substance capable of inhibiting the production of IL-2. The production of IL-2 can be inhibited with a compound represented by general formula (I) (wherein R1 to R4 and A are as defined i...  
WO/2014/150873A1
Sequestrants of AGE precursors comprise amines separated by 2, 3 or 4 carbons. Sequestrants of AGE precursors can be used as pharmaceutical agents and in pharmaceutical compositions. The sequestrants of AGE precursors are particularly us...  
WO/2014/147636A8
The present invention relates to novel quinoline compounds of formula (I), and their pharmaceutically acceptable salts and process for their preparation. The compounds of formula (I) are useful in the treatment of various disorders that ...  
WO/2014/148951A1
The invention relates to the field of medicine, and more particularly to psychopharmacology and psychoneurology. A combination of drugs comprising various active agents, which do not have a direct analgesic effect, in conjunction with on...  
WO/2014/147636A1
The present invention relates to novel quinoline compounds of formula (I), and their pharmaceutically acceptable salts and process for their preparation. The compounds of formula (I) are useful in the treatment of various disorders that ...  
WO/2014/152818A1
Described herein are methods of inhibiting or reversing the progression of cataract formation or presbyopia in an eye by administering a γ-crystallin charge masking agent. Both presbyopia and cataracts are caused by aggregation of the s...  
WO/2014/146747A1
Compounds of the formula (I), in which R, X1, X2, X3, X4, R1, R2 and q have the meanings indicated in Claim 1, are inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiova...  
WO/2014/152537A1
The present invention is directed to a compound of Formula (I) Formula (I) The invention also relates to pharmaceutical compositions comprising compounds of Formula (I) and methods comprising administering to a subject at least one compo...  
WO/2014/148646A1
The present invention addresses the problems of: providing a method for producing motor neurons from pluripotent stem cells quickly and in synchronisation, said motor neurons being satisfactorily provided with the properties of inherent ...  
WO/2014/146699A1
The invention relates to antagonists of the cannabinoid receptor CBI for use in the treatment and prevention of diseases associated with neural dendritic abnormalities, such as Down's syndrome, Angelman's syndrome, Rett syndrome and tube...  
WO/2014/150344A1
In its many embodiments, the present invention provides certain C2-azaspirosubstituted iminothiazine dioxide compounds. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various...  
WO/2014/149266A3
Acellular compositions for treating inflammation, comprising two or more of IL1-ra, sTNF-R1, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-β1, and sIL-1RII. Components of the acellular compositions may be derived from biologic ...  

Matches 301 - 350 out of 103,389